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Abstract
Background: Whether HIV viremia, particularly at low levels is associated with inflammation, increased coagulation, and all-
cause mortality is unclear.
Methods: The associations of HIV RNA level with C-reactive protein (CRP), fibrinogen, interleukin (IL)-6 and mortality were
evaluated in 1116 HIV-infected participants from the Study of Fat Redistribution and Metabolic Change in HIV infection. HIV
RNA level was categorized as undetectable (i.e., ‘‘target not detected’’), 1–19, 20–399, 400–9999, and $10,000 copies/ml.
Covariates included demographics, lifestyle, adipose tissue, and HIV-related factors.
Results: HIV RNA level had little association with CRP. Categories of HIV RNA below 10,000 copies/ml had similar levels of IL-
6 compared with an undetectable HIV RNA level, while HIV RNA $10,000 copies/ml was associated with 89% higher IL-6
(p,0.001). This association was attenuated by ,50% after adjustment for CD4+ cell count. Higher HIV RNA was associated
with higher fibrinogen. Compared to an undetectable HIV RNA level, fibrinogen was 0.6%, 1.9%, 4.5%, 4.6%, and 9.4%
higher across HIV RNA categories, respectively, and statistically significant at the highest level (p=0.0002 for HIV RNA
$10,000 copies/ml). Higher HIV RNA was associated with mortality during follow-up in unadjusted analysis, but showed
little association after adjustment for CD4+ cell count and inflammation.
Conclusion: HIV RNA $10,000 copies/ml was associated with higher IL-6 and fibrinogen, but lower levels of viremia
appeared similar, and there was little association with CRP. The relationship of HIV RNA with IL-6 was strongly affected by
CD4 cell depletion. After adjustment for CD4+ cell count and inflammation, viremia did not appear to be substantially
associated with mortality risk over 5 years.
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Introduction
Chronic inflammation and increased hemostasis in HIV-
infected persons are thought to be a consequence of viral
replication or persistence and its associated immune activation.
Increased levels of inflammatory and coagulation markers have
been associated with increased mortality in HIV-infected partic-
ipants [1,2]. In the Study of Fat Redistribution and Metabolic
Change in HIV infection (FRAM), we previously reported that
markers of inflammation and coagulation remain important
predictors of death even at higher CD4+ cell counts [2].
Whether low levels of viremia predispose to increased inflam-
mation is unclear. Many patients on antiretroviral therapy (ART)
with undetectable viremia by conventional assays have been shown
to have persistent low level viremia when a more sensitive research
assay (limit of detection ,3.5copies/ml) was used [3]. Studies
[1,4,5] that have used conventional HIV RNA assays suggest that
inflammation may persist despite having undetectable HIV RNA.
In one small study, elite controllers (HIV-infected persons with
undetectable HIV RNA in the absence of ART) had higher levels of
the inflammatory marker C-reactive protein (CRP) than HIV-
uninfected controls [4]. In the SMART trial [5], levels of CRP,
interleukin (IL)-6 and D-dimer remained elevated in persons with
HIV infection even after suppression of HIV RNA with ART. The
SMART trial also showed that IL-6 and D-dimer were strongly
associated with mortality even in HIV-infected adults who achieved
viral suppression [1]. These studies used HIV RNA assays with a
lower limit of detection of 75 copies/ml [4] and 400 copies/ml [1].
Using a recently approved ultrasensitive HIV RNA assay, we
evaluated the association of viremia with CRP, the pro-
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HIV-infected participants of the FRAM study. We then examined
whether HIV RNA levels were associated with increased all-cause
mortality risk after adjusting for demographic and cardiovascular
risk factors, CD4+ cell count, and markers of inflammation and
coagulation. We hypothesized that even very low levels of viremia
would be associated with ongoing inflammation.
Methods
Ethics Statement
The Committee on Human Research at the University of
California, San Francisco approved the Office of the Principal
Investigator at the University of California, San Francisco to
oversee all data collection activities for this multicenter study at 16
sites across the United States, for both FRAM exams. The
approved protocol includes the investigation of markers of
infection and inflammation and their association with adipose
tissue changes, metabolic perturbations and their long term
consequences. Approval for data collection activities by the
Institutional Review Board (IRB) at each respective site were also
obtained including the University Hospitals Case Medical Center
IRB, the Tufts Medical Center/Tufts University IRB, and the
Stanford IRB and the Research and Human Subjects Review
Committee of Santa Clara Valley Medical Center (the full name of
all data collection sites and their IRB are listed in the Appendix
S1). Written informed consent was obtained from all participants.
All clinical investigation was conducted according to the principles
expressed in the Declaration of Helsinki.
Study Population
FRAM is a large, nationally representative, multicenter study of
HIV infection, originally designed to evaluate the prevalence and
correlates of changes in fat distribution and metabolic parameters.
The methods, design, and sample characteristics of the FRAM
cohort have been described previously [6]. Briefly, between June
2000 and September 2002, 1183 HIV-infected men and women
from 16 geographically diverse sites across the United States were
enrolled in FRAM, with a follow-up exam conducted approxi-
mately five years later (FRAM2) (2004–2007). Retention outcomes
for participants enrolled in the first exam have been reported [7]. At
the second exam, 922 HIV-infected participants were known to be
alive or dead; vital status could not be determined for the remaining
261 HIV-infected participants. Linkage to the National Death
Index was not possible because of institutional review board and
patient confidentiality issues. The second exam included 581 HIV-
infected participants recruited from those seen at the first exam.
Study measurements
HIV viral load. As previously reported [6] , at both visits,
blood specimens were analyzed in a single centralized laboratory
(Covance, Indianapolis, Indiana), including a standard lipid panel,
CD4+ lymphocyte count and HIV RNA (Roche COBASH
AMPLICOR HIV-1 Monitor Test; lower limit of quantitation:
400copies/ml).Forthisstudy,a single 1-mlaliquotsampleoffrozen
plasma for each visit (FRAM1 and FRAM2) was retested using the
FDA-approved COBASH AmpliPrep/COBASH TaqManH HIV-1
Test, version 2.0 (Roche Molecular Diagnostics, RMD). The
approved lower limit of quantitation and detection for the assay is
20 copies/ml. For values below 20 copies/ml, clinical results are
reported as ‘‘,20 copies/ml detectable’’ or ‘‘,20 copies/ml
undetectable.’’ For the purposes of our study, RMD provided
actual values below the limit of 20 copies/ml, that ranged from 0 to
19. A value of 0 indicates that the test did not detect copies of virus
(i.e. ‘‘target not detected’’), but does not necessarily mean that the
true HIV RNA level was 0 copies/ml given the imprecision of the
test at extremely low levels of virus. The two timepoints (FRAM1
and FRAM2) were used separately to predict inflammation.
Inflammatory Biomarkers. As described previously [8,9],
CRP and fibrinogen were quantitatively measured in frozen sera
and plasma, respectively (i.e., stored at 270 degrees Celsius and not
previously thawed) at both the first and second FRAM examination
using the BNII nephelometer from Dade Behring (Deerfield, IL)
which utilizes a particle-enhanced immunonephelometric assay.
The lower limit of detection for the ultrasensitive CRP assay used in
FRAM was 0.16 mg/L. The inter-assay coefficient of variation
(CV) for CRP ranged from 3.7% to 4.5%. The intra- and inter-
assay CV for fibrinogen was 2.7% and 2.6% respectively. IL-6 was
measured from frozen sera collected at the second FRAM
examination by ultrasensitive enzyme-linked immunosorbent
assay (Quantikine HS Human IL-6 Immunoassay; R&D Systems).
The lower limit of detection was 0.16 pg/mL. The intra-assay CV
for IL-6 was 6.3%. Based on 3–4 controls per assay, the inter-assay
CV ranged from 7% to 15% for IL-6. CRP, fibrinogen, and IL-6
were measured at the Laboratory for Clinical Biochemistry
Research at the University of Vermont or the University of
California, San Francisco.
Covariates. Covariates were collected at both examinations.
Clinical information was collected using standardized questionnaires,
laboratory, and anthropometric measurement protocols. The
following information was considered for inclusion in multivariable
models of CRP, fibrinogen, and IL-6: demographic characteristics
(age, sex, and race), lifestyle factors (physical activity, alcohol use,
adequate food intake, and smoking), regional and total adipose tissue
(as described previously [10]), and HIV-related factors (HIV RNA
level, CD4+ cell count, AIDS [11], duration of HIV infection, and
HCV infection [defined by detectable HCV RNA]).
In models of mortality, covariates from the first exam included
demographics, traditional cardiovascular disease risk factors
(diabetes, smoking, blood pressure, and HDL and total cholester-
ol), CD4+ cell count, and markers of inflammation (CRP and
fibrinogen). Multiple imputation using the Markov chain Monte
Carlo method was used to impute missing covariates [12].
Statistical analysis
Of the 1183 HIV-infected participants enrolled in FRAM, 1116
had available HIV RNA data and were included in the analysis.
We compared demographic and clinical characteristics at baseline
across levels of HIV RNA using the Kruskal-Wallis test for
continuous variables and a chi-squared test for categorical
variables. We discretized HIV RNA as follows: 0, 1–19, 20–399,
400–9999, and $10,000 copies/mL.
We tested the linearity assumption for the relationship of HIV
RNA with inflammatory markers and mortality by examining
generalized additive models [13]. We used multivariable linear
regression to evaluate the association of HIV RNA at each exam
with CRP, fibrinogen, and IL-6. To account for repeated
measures from the two exams (FRAM1 and FRAM2), linear
mixed models with random intercepts and slopes were used to
evaluate the association of HIV RNA with CRP and fibrinogen.
IL-6 data was only available in FRAM2. All analyses were
adjusted using inverse probability weighting to address the impact
of selection bias [14].
We adjusted for covariates in stages, first including demograph-
ics variables (age, gender, and race), then adding lifestyle factors,
regional adipose tissue depots, and finally adding HIV-related
factors to the model. The final multivariate-adjusted models were
built separately for each outcome (CRP, fibrinogen, and IL-6)
HIV Viremia, Inflammation, and Mortality
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and retention of covariates.
As in previous analyses [2,15], we used multivariable logistic
regression to evaluate the association of baseline HIV RNA with
cumulative 5-year mortality. Since the exact dates of death were
unknown, those who died provided left-censored observations,
meaning that death was only known to have occurred sometime
before the contact attempt at approximately 5 years of follow-up.
We therefore used logistic regression with an offset term for follow-
up time, rather than Cox proportional hazards regression as our
primary analysis, because this form of regression is appropriate for
left-censored events. Follow-up time was defined as elapsed time
from baseline to follow-up exam or last contact. To account for
those with missing vital status, we also adjusted estimates using an
inverse probability weighting approach by modeling the partici-
pant’s probability of having known death status [14]. The inverse
of this probability was then used as a weight applied to persons
with known vital status in the logistic regression analysis of death.
All analyses were conducted using the SAS system, version 9.2
(SAS Institute, Inc., Cary, North Carolina).
Results
At baseline, the overall median age of the study participants was
42 years. Women comprised 30% of the study population. The
overall median value for HIV RNA was 280 copies/ml. Table 1
presents the baseline demographic and clinical characteristics of the
1,116 HIV-infected participants stratified by HIV RNA level (0
copies/ml, 1–19 copies/ml, 20–399 copies/ml, 400–10,000 copies/
ml, and $10,000 copies/ml). Participants with higher HIV RNA
were more often African-American, had lower visceral adipose
tissue (VAT) and higher leg subcutaneous adipose tissue (SAT), and
were more often smokers, injection drug users, and HCV-infected.
Those with higher HIV RNA also were less often HAART users
andhadlowerrates ofARTadherenceand lowerCD4+ cell counts.
Current smoking was less frequent in those with 0 copies/ml
compared to those with 1–19 copies/ml (29% vs. 43%, p=0.0019).
Median CD4+ cell count appeared to be slightly higher in those
with 0 copies/ml compared to those with 1–19, but the difference
did not reach statistical significance (484 vs. 453, p=0.27).
Association of continuous and categorized HIV RNA
levels with CRP
There appeared to be little overall association of HIV RNA
level with CRP in unadjusted analysis (p=0.99, test for linear
association). Examination of generalized additive models suggested
some evidence of non-linearity (p=0.054), with higher predicted
levels of CRP among those with very high levels of viremia
(.100,000 copies/ml). However, the variation in CRP was very
wide at these very high levels of viremia, and only 86 study
participants had levels of HIV RNA above 100,000 copies/ml.
Therefore, we examined the association of categorized HIV
RNA levels with CRP (Table 2 and Figure 1A) using multivariable
linear regression analysis. After adjustment for demographics,
lifestyle factors, and adipose tissue, any HIV RNA level still
showed little association with CRP. Further adjustment for HIV-
Table 1. Baseline demographic and clinical characteristics of HIV-infected participants by HIV viral load category.
Viral Load (copies) P-value
0 1–19 20–399 400-10K .10K
N 210 137 236 237 296
Age (y) 43.5 (38.0–50.0) 42.0 (37.0–49.0) 42.5 (37.0–49.0) 43.0 (36.0–48.0) 42.0 (36.5–47.0) 0.18
Female 65 (31.0%) 36 (26.3%) 58 (24.6%) 74 (31.2%) 97 (32.8%) 0.24
Race
Caucasian 117 (55.7%) 79 (57.7%) 130 (55.1%) 85 (35.9%) 124 (41.9%) ,.0001
Black 63 (30.0%) 42 (30.7%) 81 (34.3%) 117 (49.4%) 140 (47.3%)
Hispanic 23 (11.0%) 13 (9.5%) 21 (8.9%) 28 (11.8%) 26 (8.8%)
Other 7 (3.3%) 3 (2.2%) 4 (1.7%) 7 (3.0%) 6 (2.0%)
BMI (kg/m
2) 25.2 (22.4–28.7) 24.7 (22.7–26.9) 24.2 (22.3–26.7) 25.1 (22.5–29.1) 24.5 (21.7–27.9) 0.046
VAT (kg) 2.1 (1.0–3.1) 1.9 (0.9–3.0) 1.4 (0.6–2.6) 1.5 (0.6–2.4) 1.1 (0.5–2.2) ,.0001
Leg SAT (kg) 3.0 (1.9–5.4) 2.6 (1.9–4.8) 3.2 (1.9–4.9) 3.4 (2.1–5.4) 3.6 (2.2–6.1) 0.0019
Smoking Status
Current 61 (29.0%) 59 (43.1%) 93 (39.4%) 105 (44.3%) 136 (45.9%) 0.0001
Past 40 (19.0%) 33 (24.1%) 66 (28.0%) 45 (19.0%) 60 (20.3%)
Never 109 (51.9%) 45 (32.8%) 77 (32.6%) 87 (36.7%) 100 (33.8%)
Alcohol 87 (41.4%) 49 (35.8%) 92 (39.0%) 101 (42.6%) 123 (41.6%) 0.71
IDU 29 (13.8%) 26 (19.0%) 48 (20.3%) 49 (20.7%) 82 (27.7%) 0.0047
HCV 32 (15.2%) 25 (18.2%) 54 (22.9%) 61 (25.7%) 72 (24.3%) 0.045
Current HAART 195 (92.9%) 128 (94.1%) 197 (83.8%) 154 (65.0%) 177 (60.2%) ,.0001
ART Adherent (y/n) 167 (81.9%) 110 (82.1%) 176 (81.9%) 130 (68.8%) 127 (67.6%) ,.0001
Current CD4 (cells/uL) 484 (315–660) 453 (275–617) 395 (262–578) 378 (255–528) 189 (77–346) ,.0001
Data above are summarized as median (IQR) or number (percent). Analysis is restricted to those with non-missing inflammatory markers.
BMI=body mass index, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, IDU=injection drug user, HCV=hepatitis C virus, HAART=highly active
antiretroviral therapy, ART=antiretroviral therapy.
doi:10.1371/journal.pone.0026320.t001
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RNA with CRP (Figure 1A).
Association of continuous and categorized HIV RNA
levels with IL-6
Increasing HIV RNA level was associated with IL-6 in
unadjusted analysis (p=0.0031, test for linear association).
Examination of generalized additive models suggested evidence
of non-linearity (p=0.045), with a steeper slope seen among those
with higher levels of viremia.
In the multivariable analysis of categorized HIV RNA levels,
after adjustment for demographic, lifestyle factors, and adipose
tissue, participants with HIV RNA levels below 10,000 copies/ml
had levels of IL-6 that were similar to those with zero copies
(Figure 1B and Table 2). By contrast, those with HIV RNA above
10,000 copies/ml had 89% higher IL-6 (p,.0001 versus those
with zero copies). This association was attenuated by approxi-
mately 50% after further adjustment for CD4+ cell count
(p=0.022 versus those with zero copies).
Association of continuous and categorized HIV RNA
levels with fibrinogen
Increasing HIV RNA level was more strongly associated with
fibrinogen in unadjusted analysis (p,.0001, test for linear
association). Examination of generalized additive models suggested
evidence of non-linearity (p=0.0048), with a steeper slope seen
among those with higher levels of viremia (especially $10,000
copies/mL).
In multivariable analysis of categorized HIV RNA levels, after
adjustment for demographic, lifestyle factors, and adipose tissue,
increasing HIV RNA was associated with higher fibrinogen
(Table 2 and Figure 1C). Results were similar after further
adjustment for HIV-related factors.
Interaction and sensitivity analyses
Because we found that the association of HIV RNA with IL-6 was
attenuated by CD4+ cell count, we tested for CD4 by HIV RNA
interaction for each inflammatory marker. There were no statistically
significant interactions on CRP, IL-6, or fibrinogen. As expected, we
found that IL-6 and fibrinogen were highest in those with HIV RNA
$10,000 copies/ml and CD4+ cell count ,200 (data not shown).
In order to examine whether these associations persisted when
limited to those on ART, we performed a sensitivity analysis
excluding those not on ART. All associations were similar (data
not shown).
Association of HIV RNA level with all-cause mortality
In unadjusted analysis, five-year all-cause mortality progressive-
ly increased with increasing HIV RNA level (p,.0001, Figure 2).
The prevalence of death ranged from 6.8% among those with zero
HIV RNA copies to 23% among those with $10,000 copies/ml.
In demographic-adjusted analysis, the odds of mortality increased
by 39% for every 10-fold increase in HIV RNA (p,.0001).
However, the association of HIV RNA with mortality was
attenuated after adjustment for CD4+ cell count (OR: 1.07, 95%
CI: 0.95, 1.21, p=0.23), and there appeared to be no association
after further adjustment for cardiovascular risk factors and
inflammation (OR: 0.99, p=0.90).
Controlling for duration of ART use did not change the
association of HIV RNA with mortality (OR=1.01, 95%CI:
0.89–1.15, p=0.91). There were no statistically significant
interactions of HIV RNA with CRP, fibrinogen, or CD4+ cell
count on mortality.
Discussion
Our study is one of the first to examine the association of low
level viremia with inflammatory biomarkers and mortality in a
large, nationally representative cohort of HIV-infected adults
which allowed for a fully developed multivariable analysis.
Contrary to our hypothesis, we found little association of low
level viremia with levels of CRP, IL-6 and fibrinogen. Rather,
there was little association of any HIV RNA level with CRP, and
only HIV RNA level $10,000 copies/ml had a relatively strong
association with IL-6 and fibrinogen levels.
Table 2. Association of discretized HIV RNA levels with CRP, IL-6, and fibrinogen in all HIV-infected participants.
Outcome
Model Level of Viral Load CRP IL-6 Fibrinogen
%Estimate (95% CI) %Estimate (95% CI) %Estimate (95% CI)
Demographics + Lifestyle + Adipose Tissue
VL 1–19 vs. VL=0 4.8 (213.0, 26.3) p=0.62 0.8 (225.7, 36.7) p=0.96 0.5 (24.6, 5.8) p=0.86
VL 20–399 vs. VL=0 29.1 (223.1, 7.5) p=0.26 2.0 (222.6, 34.5) p=0.89 1.7 (22.9, 6.5) p=0.48
VL 400-1K vs. VL=0 211.9 (234.4, 18.2) p=0.40 3.4 (242.4, 85.9) p=0.91 3.2 (24.8, 12.0) p=0.44
VL 1K-10K vs. VL=0 212.0 (227.9, 7.5) p=0.21 29.4 (238.9, 34.2) p=0.62 2.4 (23.0, 8.2) p=0.39
VL.10K vs. VL=0 9.5 (28.2, 30.5) p=0.31 89.2 (40.2, 155.4) p,.0001 10.0 (4.9, 15.4) p,.0001
Demographics + Lifestyle + Adipose Tissue + HIV-related
VL 1–19 vs. VL=0 5.4 (212.3, 26.7) p=0.57 0.1 (226.0, 35.5) p=0.99 0.6 (24.3, 5.9) p=0.81
VL 20–399 vs. VL=0 29.2 (223.0, 7.2) p=0.25 0.7 (223.5, 32.6) p=0.96 1.9 (22.6, 6.7) p=0.41
VL 400-1K vs. VL=0 28.8 (231.8, 22.1) p=0.54 22.5 (245.6, 74.8) p=0.93 4.5 (23.6, 13.2) p=0.29
VL 1K-10K vs. VL=0 210.1 (226.3, 9.7) p=0.29 214.7 (242.5, 26.4) p=0.43 4.6 (21.0, 10.5) p=0.11
VL.10K vs. VL=0 5.2 (211.6, 25.2) p=0.57 48.9 (5.8, 109.6) p=0.022 9.4 (4.3, 14.6) p=0.0002
CRP and Fibrinogen are analyzed using linear mixed models, with adjustment for time (baseline and year 5 data).
IL-6 is analyzed using year 5data only.
doi:10.1371/journal.pone.0026320.t002
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that increasing HIV RNA was progressively associated with higher
fibrinogen levels, whereas those with HIV RNA level ,10,000
copies/ml did not appear to have progressively higher IL-6 levels.
Second, the association of increasing viremia with higher fibrinogen
did not appear to be attenuated by immune status, whereas the
association with IL-6 was strongly attenuated by CD4+ cell count.
These findings suggest that the mechanisms by which HIV affects
inflammatory and coagulation markers are different. Finally, after
adjustment for CD4+ cell count, and inflammatory and coagulation
markers, HIV RNA did not appear to be associated with mortality.
A recent studyfrom the ATHENAcohortfound that lowlevel (HIV
RNA 50–400 copies/ml) and high level viremia (HIV RNA .400
copies/ml) were associated with 1.6-fold and 1.5-fold higher risks of
death (respectively) compared with undetectable viremia, but the
associations did not reach statistical significance, and the study did
not adjust for inflammatory and coagulation markers [16].
Our finding that low level viremia had little association with
CRP, fibrinogen, and IL-6 was somewhat unexpected. Data from
small studies of specific populations of HIV-infected patients suggest
a possible association based on other indices of inflammation
[17,18,19]. In one study of 23 patients on combination ART for a
median of 84 months [18], residual HIV replication ,50 copies/ml
was observed, and in those with poor immunologic response to
ART (i.e. gain of ,200 CD4 cells), the residual viremia was
associated with activation of CD4+ and CD8+ T-cells. In two other
small studies [17,19], HIV controllers (i.e., those with undetectable
virus using conventional assays despite the absence of ART)
demonstrated abnormal immune responses. In one, cellular HIV
RNA and DNA levels were associated with greater %CD38+ HLA-
DR+ CD4+ and HIVgagresponsive T cells
17. Inthe other,lowlevel
viremia was associated with higher HIV-1- neutralizing antibody
levels
19. By contrast, a recent study of 127 HIV-infected persons
found that low level viremia (,50 copies/ml) had little association
with markers of immune activation, and had no statistically
significant association with CRP, IL-6 or D-dimer [20].
We observed a significant association of viremia with fibrinogen
and IL-6 at levels well above the lower limit of detection for
conventional HIV RNA assays. Our findings should be compared
to data from the SMART trial [1]. In that study, changes in IL-6
and D-dimer levels were measured in 132 previously suppressed
subjects, stratified by HIV RNA category one month after
discontinuing ART (,400, 401–10,000, 10,000–50,000, and
$50,000 copies/ml). That study found significant increases in
Figure 1. Multivariable-adjusted association of HIV RNA with (A) CRP*, (B) IL-6
{, (C) fibrinogen
¥. * (A) Estimates from multivariable-
adjusted model controlling for gender, age, race, smoking, physical activity, VAT, Arm SAT, nadir CD4, and HCV status.
{ (B) Estimates from
multivariable-adjusted model controlling for gender, age, race, smoking, and current CD4.
¥ (C) Estimates from multivariable-adjusted model
controlling for gender, age, race, smoking, alcohol, upper trunk SAT, nadir CD4, HIV duration, and HCV status.
doi:10.1371/journal.pone.0026320.g001
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the increase in patients whose HIV RNA rose above 50,000
copies/ml one month after discontinuation appeared appreciably
greater than those who remained suppressed (,400 copies/ml).
Our study found that the association of HIV RNA with IL-6
was strongly attenuated after adjustment for CD4+ cell count
suggesting that immunosuppression is an important determinant
of IL-6 levels. Those with both high viremia and low CD4+ cell
count were most likely to have high IL-6 levels. In the SMART
trial, IL-6 levels were a strong predictor of mortality. By contrast,
the association of HIV RNA with fibrinogen showed little
attenuation after adjusting for CD4+ cell count, suggesting that
immunosuppression does not significantly affect fibrinogen levels.
We previously found that the association of fibrinogen with
increased mortality risk was also independent of CD4+ cell count
[2]. It is therefore of interest that we observed that greater HIV
RNA levels did not predict substantially increased mortality in
models that included both CD4+ cell count and fibrinogen.
Finally, the reasons for the lack of a significant association of HIV
RNA with CRP are unclear. We previously reported that the median
CRP in our cohort [9] was well below 3 mg/L. In the general
population, CRP levels above 3 mg/L are considered high risk for
cardiovascular disease [21]. HIV-infected participants in our cohort
had higher median CRP and fibrinogen levels than controls [8,9].
Similar to a recent study that compared HIV-infected participants
from the SMART trial with control participants from the Coronary
Artery Risk Development in Young Adults (CARDIA) Study [5], we
found that median IL-6 levels were higher in HIV-infected than
control participants (1.11 vs. 0.88 pg/ml).
There are limitations to our study. First, because of the nature of
our cohort study, we were not able to assess low level viremia from
a very large volume of plasma or using a single copy assay, and
therefore the reported values at ranges ,20 copies/ml may not be
accurate. However, this new assay was strongly correlated with the
COBASH AMPLICOR HIV-1 Monitor Test (lower limit of
detection: 400 copies/ml) originally used in our cohort. Further-
more, the distribution of clinical characteristics by HIV RNA
category (even at very low levels of virus) was in the expected
direction. Second, our study was limited by the frequency of
sampling, as viremia was assessed at only two timepoints, and by
the limited number of inflammation and coagulation markers
studied (although the select markers studied allowed comparison
with similar markers examined in prior studies). Third, IL-6 was
not measured at the first FRAM exam, and so analyses of IL-6 are
cross-sectional and limited to participants who enrolled in FRAM
2. Fourth, death and loss- to-follow up after the first FRAM exam
may have contributed to bias in the participants enrolled in the
second FRAM exam. However, we used inverse probability
weighting to mitigate any potential bias from those who did not
enroll in the second exam. Fifth, we did not have information for
the cause of death. Finally, as with all observational studies, our
findings are subject to possible unmeasured confounding.
We conclude that there is little association of low level viremia
with levels of CRP, fibrinogen, and IL-6. Our finding that there
was little association of any level of HIV RNA with CRP raises the
possibility that CRP may not be a reliable marker of inflammation
that is caused by ongoing HIV replication or persistence.
However, HIV RNA levels $10,000 copies/ml were strongly
associated with fibrinogen and IL-6. The relationship of HIV
RNA with IL-6 (but not fibrinogen) was strongly affected by CD4
depletion. After adjustment for CD4+ cell count and inflamma-
tion, there was no apparent association of HIV RNA level with
mortality. Our findings suggest that the mechanisms by which
HIV infection induces inflammation, influences coagulation, and
causes mortality are complex. Additional study of mechanistic
pathways including markers of microbial translocation is needed.
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